EMA Issues Final Elemental Impurity Risk Management Guidance for Veterinary Medicinal Products

Details of the Update

The guidance establishes a harmonized approach to the identification, assessment, and control of elemental impurities, including heavy metals, across all categories of VMPs. It clarifies that manufacturers are required to apply risk management principles aligned with European Pharmacopoeia requirements, even for veterinary product types that were previously excluded from comparable human medicinal product guidelines.

The document sets expectations for how risk assessments should be conducted and documented, including the requirement that risk assessment outcomes be summarized within regulatory dossiers for new product submissions. For existing products, dossier updates are only required where reassessment results in changes to the submitted information.

Phased Implementation and Flexibility

For immunological veterinary medicinal products, such as vaccines, the guidance introduces a phased implementation approach. This reflects their generally low-risk profile and provides additional regulatory flexibility while maintaining alignment with overall quality and safety objectives.

The guidance also allows permitted daily exposure values for elemental impurities to be recalculated where scientifically justified, taking into account animal species, body weight, dose volume, and administration frequency. In cases where direct testing is not feasible or relevant, bibliographic data may be used to support conclusions of negligible risk.

Feedback Deadline

Not applicable. This guidance is issued as final and does not include a public feedback or consultation deadline.

Why It Matters

The guidance provides regulatory clarity by confirming that elemental impurity risk management applies consistently across all veterinary medicinal products. By aligning expectations with existing European Pharmacopoeia standards, it supports digital and procedural alignment within quality systems, promotes efficiency in regulatory submissions, and limits additional burden by introducing flexibility and phased implementation where scientifically justified.

Who This Is Relevant For

This update is relevant for Regulatory Affairs, Quality Assurance, Pharmaceutical Development, and Manufacturing teams involved in the development, submission, and lifecycle management of veterinary medicinal products, including vaccines and advanced therapies.

Next Steps

Manufacturers should review existing elemental impurity risk assessment processes across all veterinary product portfolios, including products previously considered out of scope. Regulatory dossiers should be evaluated to determine whether updates are required following reassessment, and opportunities to leverage bibliographic evidence should be considered where direct testing is impractical.

As organizations adapt to these updated EMA expectations, RegASK can support teams by continuously monitoring veterinary regulatory guidance and translating complex requirements into actionable compliance workflows. RegASK is a leading agentic AI regulatory intelligence and workflow orchestration platform that empowers global organizations in highly regulated sectors, including consumer products and life sciences, to proactively navigate complex regulatory landscapes. By combining advanced Agentic AI with experts in the loop, RegASK delivers timely predictive actionable insights and end-to-end automation, streamlining compliance processes, mitigating risks, and accelerating market access across more than 160 countries. Learn more or book a demo now.

FAQs

What are elemental impurities in veterinary medicinal products?

Elemental impurities are unwanted inorganic elements, such as heavy metals, that may be present in veterinary medicinal products and require assessment and control to ensure product safety.

Which veterinary medicinal products are covered by the EMA guidance?

The guidance applies to all VMPs, including biologicals, immunologicals (vaccines), and novel therapies.

Are immunological veterinary medicinal products subject to the same requirements?

Yes. Immunological VMPs are included, but the guidance provides a phased implementation approach and additional flexibility due to their low-risk profile.

How can RegASK help companies comply with EMA elemental impurity guidance?

RegASK helps regulatory and quality teams track EMA guidance updates, assess their impact on veterinary product portfolios, and manage risk assessment and documentation requirements through AI-driven regulatory intelligence and workflow automation.